All News

acr_session2.jpeg

ICYMI: ACR Plenaries: Changing the Practice of Rheumatology

d Kathryn H. Dao, M.D.

Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.

Read Article
pregnant.baby_.hands_.jpg

ICYMI: Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases

d Bella Mehta, MBBS, MS

Pregnant women with autoimmune rheumatic diseases (ARDs) and antiphospholipid syndrome (APS) face significantly increased risks of cardiovascular events (CVEs). This increased risk is often attributed to ARDs, its medications or comorbidities associated with it.

Read Article
Fatigue,depression

EULAR 2023 Recommendations on Fatigue

d Jack Cush, MD

Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. A EULAR task force set out to develop recommendations for the management of fatigue in people with I-RMDs.

Read Article
rare

ICYMI: Here at Last: Treatment Options for VEXAS

d Michael Putman, MD, MSCI

We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.

Read Article
uveitis eye iritis

ICYMI: Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab

d Meral K. El Ramahi, MD, FACP, FACR

Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated. 

Read Article
Sleep.fatigue.doctor.jpg

CDC: Chronic Fatigue Syndrome 2021-2022

d Jack Cush, MD

The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022).

Read Article
ICYMI: Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. https://t.co/rNSTcT5O6L https://t.co/f5lvMTH7ik

Links:

Dr. John Cush RheumNow ( View Tweet)
The ARGO Project for Rheumatology Fellows Dr. Sheila Reyes (Philippines) talks with Dr. Lisa Traboco about abstract 2078, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/RRjc38JpEQ https://t.co/q9rCxbWzNh

Links:

Dr. John Cush RheumNow ( View Tweet)
When should we be starting therapy in GCA and PMR? The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind the ambiguity of therapeutic inadequacy. https://t.co/oRWTeH5Q9h https://t.co/BbswdffoKM

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date for RheumNow Live 2024, on January 27-28, in Dallas, TX, or from the comfort of your own space through our virtual platform! Why choose RheumNow Live? Because this isn't just another conference – it's a revolution in medical education! https://t.co/K2YYqjjs8F https://t.co/MinRm9N9rz

Links:

Dr. John Cush RheumNow ( View Tweet)
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/7GvzttR9HZ https://t.co/wYGiMg4zqK

Links:

Dr. John Cush RheumNow ( View Tweet)
Promising Therapies for Sjogren's Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/8iSDMKtKwa https://t.co/QCYTnpYKFN

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: SpA Sleuths: The Case of Undiagnosed IBD As rheumatologists, we are medical detectives investigating complex and often elusive autoimmune and inflammatory conditions https://t.co/dE0NLXKDvT https://t.co/DalUXRf3MB

Links:

Dr. John Cush RheumNow ( View Tweet)
CBT or Naltrexone in Fibromyalgia https://t.co/9SGRbY97oD https://t.co/wN2cMuqgHa

Links:

Dr. John Cush RheumNow ( View Tweet)
Expert consensus(ASAS) prefers SpondyloArthritis(axSpA) as preferred over "ankylosing spondylitis" (historic but no longer appropriate based on MRI research showing this is more than SI disease). AS radiographic axSpA(r-axSpA) can be used interchangeably https://t.co/jvT3lQFaPq https://t.co/WRNrbfjK1S

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish study compared 106K adults w/ major osteoporotic fracture (hip, vertebrae, wrist, humerus) vs 1+ mill controls & found Mortality highest 30d following 1st index hip Fx (HR 10.98 women; & HR 16.40 men). Pneumonia most common cause of mortality https://t.co/0D7ynN4f5L https://t.co/qX61cgq1SL

Links:

Dr. John Cush RheumNow ( View Tweet)

Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AFoKm6kT86 https://t.co/dLTjTOdbmv

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Non-TNFi b/tsDMARDs vs. TNFi in RA-ILD https://t.co/fOz4jH58r9 https://t.co/jSHnsZscPg

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiology 101 for the Rheumatologist Dr. Janet Pope reports on a cardiology session presented a 2023 ACR Convergence in San Diego, CA https://t.co/0cS8JVneIG https://t.co/6SIPx6WmqX

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Warning on CAR-T Cell Therapy The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies. https://t.co/1OiMWJMskz https://t.co/8i8LFMcb1s

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×